logo
X slams French prosecutors' ‘political' probe over algorithm manipulation and data extraction, refuses data access

X slams French prosecutors' ‘political' probe over algorithm manipulation and data extraction, refuses data access

Mint6 days ago
Elon Musk's social media platform X has accused French prosecutors of launching a "politically-motivated criminal investigation" that threatens free speech and violates legal norms. The platform, formerly known as Twitter, said it would not cooperate with the probe, denying all allegations of wrongdoing.
'X believes that this investigation is distorting French law in order to serve a political agenda and, ultimately, restrict free speech,' the company posted via its Global Government Affairs account on Monday.
Earlier this month, Paris prosecutors escalated their preliminary probe into a full criminal investigation. The focus: suspected algorithmic bias and fraudulent data extraction by X. This move gives police sweeping powers, including conducting searches, wiretaps, and placing executives under surveillance.
Authorities can now summon Musk or X executives for testimony. Should they refuse, judges may issue arrest warrants.
Prosecutors sent a judicial request on July 19 asking for access to X's recommendation algorithm and real-time data. X declined, asserting its legal right to do so.
'We refused the request as we have a legal right to do,' X said.
The Paris prosecutor's office confirmed the request and stated that a secure channel was offered to protect data confidentiality. It has not yet received an official reply from the company. Refusal to comply could result in fines or charges of obstruction of justice.
X has also objected to the case being investigated under organized crime statutes, which could allow French authorities to wiretap the personal devices of X employees.
The prosecutor's office noted that the alleged offenses carry maximum penalties of up to 10 years in prison.
Musk, a former ally of Donald Trump, has repeatedly accused European governments of suppressing free expression. The dispute is likely to intensify transatlantic tensions over content regulation.
The European Commission has been investigating X since late 2023 for suspected violations of the Digital Services Act, a law aimed at increasing transparency and accountability in digital platforms.
X claims the case was instigated by French MP Eric Bothorel, who accused the platform of algorithm manipulation for foreign interference — an allegation X called 'completely false.'
Bothorel defended the probe: 'France is committed to free speech but not without limits. The absence of responsibility and oversight endangers freedom just as much as prohibitions and censorship do,' he said.
X also criticised the involvement of researchers David Chavalarias and Maziyar Panahi, accusing them of hostility toward the platform. Panahi denied any involvement: 'My name was mentioned by mistake… I will not hesitate to pursue legal action for defamation should I receive any form of hate speech,' he said in an email.
A spokesperson for X reiterated that the company stands by its statement and continues to oppose what it sees as a dangerous precedent for politically driven investigations into free expression.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

US, EU strike trade deal with broad 15% tariff on most European goods
US, EU strike trade deal with broad 15% tariff on most European goods

First Post

time13 minutes ago

  • First Post

US, EU strike trade deal with broad 15% tariff on most European goods

The US and the EU have finalised a framework trade agreement, introducing a sweeping 15% US tariff on most European imports. read more European Commission President Ursula von der Leyen sits with U.S. President Donald Trump, after the announcement of a trade deal between the U.S. and EU, in Turnberry, Scotland, Britain. Reuters The United States struck a framework trade deal with the European Union on Sunday, imposing a 15% U.S. import tariff on most EU goods, but averting a spiralling battle between two allies which account for almost a third of global trade. The announcement came after European Commission President Ursula von der Leyen travelled for talks with U.S. President Donald Trump at his golf course in western Scotland to push a hard-fought deal over the line. STORY CONTINUES BELOW THIS AD

U.S. EU trade deal: Donald Trump slaps 15 per cent tariffs on European goods, auto. What is new in it? Is China next?
U.S. EU trade deal: Donald Trump slaps 15 per cent tariffs on European goods, auto. What is new in it? Is China next?

Economic Times

time13 minutes ago

  • Economic Times

U.S. EU trade deal: Donald Trump slaps 15 per cent tariffs on European goods, auto. What is new in it? Is China next?

US-Europe Trade Deal US-EU Tariffs Live Events USA-China Trade Deal Nearing? FAQs (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel US President Donald Trump and EU chief Ursula von der Leyen Sunday announced they had reached a deal to end a transatlantic tariffs standoff and avert a full-blown trade war. The agreement came as the clock ticked down on an August 1 deadline for the European Union to strike a deal with Washington -- or face an across-the-board US levy of 30 percent. Trump told reporters the deal involved a baseline levy of 15 percent on EU exports to the United States -- the same level secured by Japan -- including for the bloc's crucial auto sector, which is currently being taxed at 25 percent. Now all eyes are on the world's second largest economy - US President also said the bloc had agreed to purchase "$750 billion worth of energy" from the United States, as well as $600 billion more in additional investments in the country. Negotiating on behalf of the EU's 27 countries, von der Leyen's European Commission had been pushing hard to salvage a trading relationship worth an annual $1.9 trillion in goods and EU has been hit by multiple waves of tariffs since Trump reclaimed the White House. It is currently subject to a 25-percent levy on cars, 50 percent on steel and aluminium, and an across-the-board tariff of 10 percent, which Washington threatens to hike to 30 percent in a no-deal 15 percent would be much higher than pre-existing US tariffs on European goods, which average around 4.8 percent, it would mirror the status quo, with companies currently facing an additional flat rate of 10 the talks failed, EU states had greenlit counter tariffs on $109 billion (93 billion euros) of US goods including aircraft and cars to take effect in stages from August 7. Brussels was also drawing up a list of US services to potentially has embarked on a campaign to reshape US trade with the world, and has vowed to hit dozens of countries with punitive tariffs if they do not reach a pact with Washington by August 1. US Commerce Secretary Howard Lutnick had said Sunday the August 1 deadline was firm and there will be "no extensions, no more grace periods".U.S. President Donald Trump said on Sunday his administration was close to reaching a trade deal with China, but gave no other details. "We're very close to a deal with China. We really sort of made a deal with China, but we'll see how that goes," Trump told reporters at the start of a meeting with European Commission President Ursula von der Leyen in Scotland.A1. While 15 percent would be much higher than pre-existing US tariffs on European goods, which average around 4.8 percent, it would mirror the status quo, with companies currently facing an additional flat rate of 10 percent.A2. US President Donald Trump also said the bloc had agreed to purchase "$750 billion worth of energy" from the United States, as well as $600 billion more in additional investments in the country.

Cheaper cancer care therapy earns big bucks for pharma company
Cheaper cancer care therapy earns big bucks for pharma company

Economic Times

time13 minutes ago

  • Economic Times

Cheaper cancer care therapy earns big bucks for pharma company

India's cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations, a rare feat in the country's emerging startup landscape where research-based pharma enterprises encounter serious scale and cash flow challenges. ImmunoACT, in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with a profit before tax of ₹12 crore in FY25, according to sources. The year before, ImmunoAct had revenues of ₹11 crore. Founded by immunologist Rahul Purwar in 2013, ImmunoACT was spun off from the department of bioengineering department of IIT Bombay in 2018. ImmunoACT's NexCAR19 is the first indigenously developed breakthrough cancer CAR-T (chimeric antigen receptor T-cell) therapy approved by India's central drug regulatory agency in October 2023. NexCAR19 was formally launched in India in April 2024 at a price ~90% cheaper than its US and European counterparts like Novartis and Gilead, making it far more affordable for India and low-and-middle income countries, on its potential approval. So far, the therapy has been infused in over 350 patients across 70 hospitals in India. In CAR-T treatment, the patient's immune cells are extracted and through a maze of re-engineering processes infused back to recognize and kill cancer cells, giving a longer remission to patients as compared to the conventional options like immunotherapy or bone marrow transplants. The therapy is used when all other options are CAR-T dose (one-and-done infusion) costs around ₹30 lakh, which was initially priced at ₹42 lakh, and is expected to see a further decline as demand picks ImmunoACT has recently appointed former managing director of Roche India V Simpson Immanuel as its strategic Purwar added, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion." Earlier this year, Immuneel Therapeutics, backed by leading names like Kiran Mazumdar-Shaw and globally renowned oncologist Siddhartha Mukherjee secured approval for Qartemi, its cell therapy for adult B-cell non-Hodgkin Lymphoma, in India. Companies like Cipla, Dr Reddy's Labs and Bharat Biotech are investing heavily in new CAR-Ts. Globally, CAR-Ts are at the frontiers of a range of cancer treatments, attracting billions of dollars in investments from large drugmakers. The market for such therapies is expected to touch $134 billion by 2034 from around $10 billion at present.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store